215 related articles for article (PubMed ID: 29590326)
1. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
Benson CA; Andersen JW; Macatangay BJC; Mailliard RB; Rinaldo CR; Read S; Bozzolo DR; Purdue L; Jennings C; Keefer MC; Glesby M; Tebas P; Russell AF; Martin J; Annunziato P; Popmihajlov Z; Lennox JL
Clin Infect Dis; 2018 Nov; 67(11):1712-1719. PubMed ID: 29590326
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
Berkowitz EM; Moyle G; Stellbrink HJ; Schürmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC;
J Infect Dis; 2015 Apr; 211(8):1279-87. PubMed ID: 25371534
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
[TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
[TBL] [Abstract][Full Text] [Related]
7. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
[TBL] [Abstract][Full Text] [Related]
8. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Winthrop KL; Wouters AG; Choy EH; Soma K; Hodge JA; Nduaka CI; Biswas P; Needle E; Passador S; Mojcik CF; Rigby WF
Arthritis Rheumatol; 2017 Oct; 69(10):1969-1977. PubMed ID: 28845577
[TBL] [Abstract][Full Text] [Related]
9. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
Levin MJ; Schmader KE; Gnann JW; McNeil SA; Vesikari T; Betts RF; Keay S; Stek JE; Bundick ND; Su SC; Zhao Y; Li X; Chan IS; Annunziato PW; Parrino J
J Infect Dis; 2013 Nov; 208(9):1386-90. PubMed ID: 23908486
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z
Clin Infect Dis; 2017 Oct; 65(7):1174-1182. PubMed ID: 29126292
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
Schmader KE; Levin MJ; Gnann JW; McNeil SA; Vesikari T; Betts RF; Keay S; Stek JE; Bundick ND; Su SC; Zhao Y; Li X; Chan IS; Annunziato PW; Parrino J
Clin Infect Dis; 2012 Apr; 54(7):922-8. PubMed ID: 22291101
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL
Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932
[TBL] [Abstract][Full Text] [Related]
15. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
Mullane KM; Winston DJ; Wertheim MS; Betts RF; Poretz DM; Camacho LH; Pergam SA; Mullane MR; Stek JE; Sterling TM; Zhao Y; Manoff SB; Annunziato PW
J Infect Dis; 2013 Nov; 208(9):1375-85. PubMed ID: 23908479
[TBL] [Abstract][Full Text] [Related]
18. Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
Weinberg A; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Levin MJ
J Infect Dis; 2018 Sep; 218(suppl_2):S81-S87. PubMed ID: 30247596
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
[TBL] [Abstract][Full Text] [Related]
20. Th1 memory differentiates recombinant from live herpes zoster vaccines.
Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
